Harvard Bioscience, Inc. (HBIO) Short Interest Up 36.0% in January
Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,234,762 shares, an increase of 36.0% from the January 15th total of 907,584 shares. Based on an average daily trading volume, of 179,638 shares, the days-to-cover ratio is currently 6.9 days. Currently, 3.8% of the shares of the stock are sold short.
Shares of HBIO opened at $3.66 on Thursday. The company has a quick ratio of 1.49, a current ratio of 2.83 and a debt-to-equity ratio of 0.73. Harvard Bioscience has a 52-week low of $2.75 and a 52-week high of $6.70. The firm has a market capitalization of $136.87 million, a price-to-earnings ratio of 73.20 and a beta of 1.38.
Separately, ValuEngine downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.
Read More: Do Tariffs Work?
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.